A Safety Study of PTI-125 in Healthy Volunteers

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03784300

Enrollment

Registered

2018-12-21

Start date

2017-08-18

Completion date

2018-03-27

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Alzheimer Disease, Early Onset

Brief summary

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Detailed description

This was a Phase I, single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy volunteers, 18 to 45 years of age. A total of twenty-four (24) subjects were enrolled into the study in one of three dose cohorts. Each cohort contained eight subjects; six subjects received PTI-125 and two received placebo. Three doses of PTI-125 oral solution (50, 100, and 200 mg) or placebo solution were administered to respective cohorts. The study included a screening period (Day -28 to Day -1), an inpatient treatment period (Day 0 through Day 4), and a follow-up visit (Day 7). Subjects reported to the clinic on the day before dosing and were randomized to receive either a single dose of orally administered PTI-125 or placebo. Each dose was administered following an overnight fast of at least 10 hours. For each dose level, dosing was staggered such that two subjects (one active and one placebo) were dosed prior to the rest of the group. After a minimum of 24 hours and review of all 24-hour safety assessments (electrocardiogram \[ECG\], a brief physical examination, vital signs, and laboratory assessments) an independent Data Safety Monitoring Board/Data Monitoring Committee (DSMB/DMC) determined whether the remaining 6 subjects were to be dosed. Pharmacokinetic blood samples were obtained prior to dosing and at specified intervals during the study (0-72 hours post-dose). Blood draws for laboratory testing were performed prior to dosing and at 24 hours post dose. After safety assessments of ECG, vital signs, and a brief physical exam at 72 hours, subjects were discharged from the clinic and returned 7 days post-dose for a final safety assessment.

Interventions

DRUG50 mg PTI-125

PTI-125 50 mg Oral Solution

DRUG100 mg PTI-125

PTI-125 100 mg Oral Solution

DRUG200 mg PTI-125

PTI-125 200 mg Oral Solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

Single center, randomized, double-blind, placebo controlled, SAD study of three escalating doses of PTI-125. A total of 24 healthy subjects enrolled in one of three dose cohorts. Each cohort will contain 8 subjects; six receive PTI-125 and two receive placebo. Three SAD does of PTI-125 oral solution (50, 100 or 200 mg) or placebo solution will be administered.

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or female subjects between 18 and 45 years of age, inclusive. * The subject has a body mass index (BMI) within 18-30 kg/m2 (inclusive). * The subject is in good health as determined by medical history and physical examination and clinical laboratory parameters. * The subject is willing and able to speak, read, and understand English and provide written informed consent. * The subject is a non-smoker for at least 12 months. If a former smoker, the reason for stopping must be evaluated. * Females who are physically incapable of childbearing defined as postmenopausal, or surgically sterile (hysterectomy, bilateral tubal ligation, bilateral oophorectomy or an Essure procedure). Appropriate documentation (ex; medical record) of the surgical sterilization procedure to be obtained and held within the subject's study file. * The subject must agree to comply with the drawing of blood samples for the PK assessments. * The subject is willing and able to comply with all testing and requirements defined in the protocol. * The subject is willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit.

Exclusion criteria

* The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator. * The subject has had a clinically significant illness within 30 days of Check-in. * The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease. * The subject has used any prescription medication within 14 days of dosing or overthe- counter (OTC) medication within 48 h of dosing or intends to use any prescription medication or OTC medication during the study that may interfere with the evaluation of study medication. * The subject has used alcohol, caffeine or xanthine-containing products 48 h before dosing or intends to use any of these products during the study. * The subject has used grapefruit, grapefruit juice, or grapefruit-containing products days before dosing or intends to use any of these products during the study. * The subject has a history of substance abuse or a positive ethanol breath test, urine cotinine, or urine drug screen at screening or at check-in. The subject has a positive serum hepatitis B surface antigen or positive HCV antibody test at the Screening Visit. * The subject has a positive HIV test at the Screening Visit. * Female subject is pregnant or breastfeeding. * The subject has received an investigational drug within 30 days of Check-in. * The subject has donated or lost a significant volume of blood (\>450 mL) within 4 weeks prior to the study. * The subject is unwilling to reside in the study unit for the duration of the study or to cooperate fully with the investigator or site personnel. * The subject has an AST/ALT or total bilirubin greater than the ULN. One repeat test will be allowed.

Design outcomes

Primary

Measure	Time frame	Description
Elimination Rate Constant (λz)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The elimination rate constant (λz) will be calculated.
Maximum Plasma Concentration (Cmax)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The peak drug concentration will be obtained directly from the data without interpolation.
Time to Maximum Plasma Concentration (Tmax) (Tmax)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The time to peak drug concentration will be obtained directly from the data without interpolation
Time to Last Quantifiable Plasma Concentration (Tlast)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation.
Last Quantifiable Plasma Concentration (Clast)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration
Termination Elimination Half-Life (T1/2)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The terminal elimination half-life (T1/2) will be calculated.
Area Under the Curve (AUC)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.
Area Under the Curve to Infinity (AUCinf)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The AUC from time zero extrapolated to infinity (AUCinf) will be calculate.
Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]).	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The percentage of AUCinf based on extrapolation (AUCextrap\[%\]).
Oral Clearance (Cl/F)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	The apparent oral clearance will be calculated.
Volume of Distribution (Vz/F)	Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.	Vz/F, apparent volume of distribution will be calculated.

Countries

United States

Participant flow

Participants by arm

Arm	Count
50 mg PTI-125 Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution	6
50 mg PTI-125 Placebo Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution	2
100 mg PTI-125 Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution	6
100 mg PTI-125 Placebo Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution	2
200 mg PTI-125 Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution	6
200 mg PTI-125 Placebo Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution	2
Total	24

Baseline characteristics

Characteristic	50 mg PTI-125 Placebo	100 mg PTI-125	100 mg PTI-125 Placebo	200 mg PTI-125	200 mg PTI-125 Placebo	50 mg PTI-125	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	2 Participants	6 Participants	2 Participants	6 Participants	2 Participants	6 Participants	24 Participants
Age, Continuous	31.8 Years	35.3 Years	31.8 Years	35.8 Years	31.8 Years	38.2 Years	35.3 Years
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	1 Participants	4 Participants	2 Participants	2 Participants	1 Participants	3 Participants	13 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	1 Participants	2 Participants	0 Participants	4 Participants	1 Participants	3 Participants	11 Participants
Region of Enrollment United States	2 Participants	6 Participants	2 Participants	6 Participants	2 Participants	6 Participants	24 Participants
Sex: Female, Male Female	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	2 Participants	4 Participants
Sex: Female, Male Male	2 Participants	5 Participants	2 Participants	5 Participants	2 Participants	4 Participants	20 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	0 / 6	0 / 2	0 / 6	0 / 2	0 / 6	0 / 2
other Total, other adverse events	0 / 6	0 / 2	1 / 6	0 / 2	1 / 6	0 / 2
serious Total, serious adverse events	0 / 6	0 / 2	0 / 6	0 / 2	0 / 6	0 / 2

Outcome results

Primary

Area Under the Curve (AUC)

The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.

Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.